Ebola vaccine

Ebola in Uganda – An Overlooked Epidemic Tinderbox, says AHF

Retrieved on: 
Wednesday, October 19, 2022
Philanthropy, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Foundation, General Health, Statens Serum Institut, Population, Vaccine, University of Oxford, AIDS Healthcare Foundation, Twitter, Instagram, Personal protective equipment, Facebook, Technology, Knowledge, PPE, Ebola vaccine, AHF, North–South divide in the World, Serum Institute of India, Death, COVID-19, Animal, Reuters

As of Oct. 17, 54 confirmed and 20 probable Ebola cases have resulted in 19 confirmed and 20 probable Ebola deathsfour were among health care workers.

Key Points: 
  • As of Oct. 17, 54 confirmed and 20 probable Ebola cases have resulted in 19 confirmed and 20 probable Ebola deathsfour were among health care workers.
  • The world must mobilize to ensure Uganda and neighboring countries implement a robust response to contain and eliminate this outbreak.
  • AHF backs all efforts to increase the availability of Ebola vaccines, which must proceed quickly, added Dr. Iutung.
  • COVID-19 proved that Africa cant rely on the Global North for support during health emergencies, and this Ebola outbreak is no different.

EDCTP and CEPI Funding Moves IAVI's Lassa fever Vaccine Candidate Into Advanced Clinical Development

Retrieved on: 
Tuesday, June 15, 2021
AIDS, Health, Other Health, General Health, Clinical trials, Research, Science, Medical specialties, Clinical medicine, Medicine, Ebola, Breakthrough therapy, Vaccines, West African Ebola virus epidemic, Lassa fever, Ebola vaccine, rVSV-ZEBOV vaccine, Vaccine, Lassa, Lassa Fever, EDCTP, CEPI, IAVI, LASSA FEVER, EDCTP, CEPI, IAVI

Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.

Key Points: 
  • Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.
  • The joint award supports an international collaboration, called Lassa Fever Vaccine Efficacy and Prevention for West Africa (LEAP4WA), to conduct a Phase IIb clinical trial of IAVIs Lassa fever vaccine candidate among adults and children in Liberia, Nigeria, and Sierra Leone.
  • LEAP4WA builds on an existing partnership with CEPI that supports IAVI and a global consortium of partners to conduct Phase I and II clinical trials of IAVIs Lassa fever vaccine candidate.
  • We are excited to apply the recombinant VSV technology, used in the previously licensed Ebola vaccine called ERVEBO, for the development of a much-needed Lassa fever vaccine.

Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization

Retrieved on: 
Thursday, February 4, 2021
Health care, Health, Clinical trials, Medicine, Novavax, Vaccine, Food and Drug Administration, European Medicines Agency, NVX-CoV2373, Ebola vaccine

The rolling review of our submission by regulatory authorities of non-clinical data and early clinical studies will help expedite the review process and bring us that much closer to delivering a safe and effective vaccine worldwide, said Gregory M. Glenn, MD, President of Research and Development, Novavax.

Key Points: 
  • The rolling review of our submission by regulatory authorities of non-clinical data and early clinical studies will help expedite the review process and bring us that much closer to delivering a safe and effective vaccine worldwide, said Gregory M. Glenn, MD, President of Research and Development, Novavax.
  • To date, Novavax has begun the rolling review process with several regulatory agencies worldwide, including the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K.
  • As part of the rolling review, the company will continue to submit additional information, including clinical and manufacturing data.
  • Novavax recombinant protein-based vaccine candidate is currently in Phase 3 clinical development in both the U.K. and U.S. for the prevention of COVID-19.

FDA Approves First Treatment for Ebola Virus

Retrieved on: 
Wednesday, October 14, 2020
Medical specialties, Medicine, Infectious diseases, Biological weapons, Tropical diseases, Zoonoses, West African Ebola virus epidemic, Ebola, Zaire ebolavirus, rVSV-ZEBOV vaccine, Ebola vaccine, Science diplomacy and pandemics

Zaire ebolavirus, commonly known as Ebola virus, is one of four Ebolavirus species that can cause a potentially fatal human disease.

Key Points: 
  • Zaire ebolavirus, commonly known as Ebola virus, is one of four Ebolavirus species that can cause a potentially fatal human disease.
  • Individuals who provide care for people with Ebola virus, including health care workers who do not use correct infection control precautions, are at the highest risk for infection.
  • Inmazeb received an Orphan Drug designation for the treatment of Ebola virus infection.
  • The FDA approved Ervebo, the first vaccine for the prevention of Ebola virus disease, in December 2019, with support from a study conducted in Guinea during the 2014-2016 Ebola outbreak.

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Marburg Virus Showing 100% Protection

Retrieved on: 
Thursday, September 3, 2020
Medical specialties, Vaccines, Medicine, Clinical medicine, Vaccine, GeoVax, Marburg virus disease, Modified vaccinia Ankara, Ebola vaccine

The study, based on research conducted in 2019, was published on September 2, 2020 in Nature Partner Journals (NPJ) Vaccines .

Key Points: 
  • The study, based on research conducted in 2019, was published on September 2, 2020 in Nature Partner Journals (NPJ) Vaccines .
  • The study demonstrated that guinea pigs vaccinated with GeoVaxs developmental MVA-MARV-VLP vaccine were 100% protected against death and disease caused by the Angola strain of Marburg virus.
  • David Dodd, GeoVax President and CEO, commented, These results demonstrated important progress in the development of our Marburg virus vaccine -- providing a basis for more advanced studies proceeding toward human safety and efficacy trials.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novelproprietaryvaccine platform (GV-MVA-VLP).

Bavarian Nordic Announces Positive Topline Results from Phase 3 Clinical Study of Freeze-dried Smallpox Vaccine

Retrieved on: 
Monday, August 24, 2020
Vaccines, Medical specialties, Vaccination, Drugs, Bavarian Nordic, Smallpox vaccine, Vaccine, Smallpox, Freeze-drying, MVA-B, Ebola vaccine

COPENHAGEN, Denmark, August 24, 2020 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today topline results from the pivotal Phase 3 study of the freeze-dried formulation of its MVA-BN smallpox vaccine.

Key Points: 
  • COPENHAGEN, Denmark, August 24, 2020 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today topline results from the pivotal Phase 3 study of the freeze-dried formulation of its MVA-BN smallpox vaccine.
  • The Phase 3 lot-consistency study was agreed with the U.S. Food and Drug Administration (FDA) as the only Phase 3 study required to support licensure of the freeze-dried formulation.
  • Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines.
  • The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX and in Canada under the trade name IMVAMUNE.

Bavarian Nordic Announces European Marketing Authorization for Ebola Vaccine

Retrieved on: 
Wednesday, July 1, 2020
Medicine, Medical specialties, Infectious diseases, Ebola, Vaccines, Ebola vaccine, Biological weapons, Tropical diseases, Zoonoses, Bavarian Nordic, Vaccine, Ebola virus disease

COPENHAGEN, Denmark, July 1, 2020 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced todaythat the European Commission has granted marketing authorization for MVABEA (MVA-BN Filo) together with ZABDENO (Ad26.ZEBOV), which collectively constitute Janssens Ebola vaccine regimen.

Key Points: 
  • COPENHAGEN, Denmark, July 1, 2020 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced todaythat the European Commission has granted marketing authorization for MVABEA (MVA-BN Filo) together with ZABDENO (Ad26.ZEBOV), which collectively constitute Janssens Ebola vaccine regimen.
  • The marketing authorization has been granted to Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson who obtained a worldwide license to develop, manufacture and commercialize MVA-BN Filo from Bavarian Nordic in 2014.
  • The Ebola vaccine regimen is specifically designed to induce long-term immunity against the Ebola virus, in adults and children aged one year and above.
  • We are proud to have supported the development of a new Ebola vaccine, which represents the second European approval of a product based on our MVA-BN platform technology, said Paul Chaplin, President & CEO of Bavarian Nordic.

Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine

Retrieved on: 
Wednesday, July 1, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, Medical devices, Infectious diseases, Clinical trials, Medicine, Infectious diseases, Ebola, Animal diseases, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Zoonoses, Ebola vaccine, Zaire ebolavirus, Ebola virus disease, Vaccine

Johnson & Johnson today announced that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies Ebola vaccine regimen for the prevention of Ebola Virus Disease.

Key Points: 
  • Johnson & Johnson today announced that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies Ebola vaccine regimen for the prevention of Ebola Virus Disease.
  • The European approval of Janssens Ebola vaccine regimen is a landmark moment both for our Company and in the worlds battle against the deadly Ebola virus.
  • Janssens Ebola vaccine regimen is specifically designed to induce long-term immunity against the Ebola virus3,4 in adults and children aged one year and above.
  • Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssens Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC).

Novavax to Participate in H.C. Wainwright Fireside Chat Series

Retrieved on: 
Wednesday, June 24, 2020
Vaccines, Novavax, Viruses, Adjuvants, Health, Vaccine, Medicine, Severe acute respiratory syndrome-related coronavirus, H5N1 clinical trials, Ebola vaccine

Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020.

Key Points: 
  • Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020.
  • NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
  • Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.
  • Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen

Retrieved on: 
Friday, June 12, 2020
Bavarian Nordic, Vaccines, Ebola vaccine, Medicine, Clinical medicine, Health, Vaccine, Janssen

Under the contract, Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.

Key Points: 
  • Under the contract, Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.
  • We are pleased to continue our strong collaboration with Janssen, said Paul Chaplin, President & CEO of Bavarian Nordic.
  • The contract builds on Bavarian Nordics existing collaboration with Janssen, under which Bavarian Nordic has previously manufactured more than 2 million doses of MVA-BN Filo.
  • Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines.